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This literature review on pseudocyesis or false pregnancy aims to find epidemiological, psychiatric/psychologic,
gynecological and endocrine traits associated with this condition in order to propose neuroendocrine/endocrine
mechanisms leading to the emergence of pseudocyetic traits. Ten women from 5 selected studies were analyzed
after applying stringent criteria to discriminate between cases of true pseudocyesis (pseudocyesis vera) versus
delusional, simulated or erroneous pseudocyesis. The analysis of the reviewed studies evidenced that pseudocyesis
shares many endocrine traits with both polycystic ovarian syndrome and major depressive disorder, although the
endocrine traits are more akin to polycystic ovarian syndrome than to major depressive disorder. Data support the
notion that pseudocyetic women may have increased sympathetic nervous system activity, dysfunction of central
nervous system catecholaminergic pathways and decreased steroid feedback inhibition of gonadotropin-releasing
hormone. Although other neuroendocrine/endocrine pathways may be involved, the neuroendocrine/endocrine
mechanisms proposed in this review may lead to the development of pseudocyetic traits including hypomenorrhea
or amenorrhea, galactorrhea, diurnal and/or nocturnal hyperprolactinemia, abdominal distension and apparent fetal
movements and labor pains at the expected date of delivery.
Keywords: Catecholamines, Hypothalamus-pituitary-ovarian axis, Major depression disorder, Polycystic ovarian
syndrome, Sympathetic nervous systemBackground
According to the fifth edition of Diagnostic and Statistical
Manual of Mental Disorders (DSM-5) [1], pseudocyesis
[from the Greek words pseudes (false) and kyesis
(pregnancy); a.k.a. false, imaginary, simulated, phantom,
hysterical or spurious pregnancy] is a rare disorder with
characteristic somatic features. It is included in the Not
Elsewhere Classified section of Somatic Symptom Disorders,
a group of disorders that typically present first in non-
psychiatric settings characterized predominantly by somatic
symptoms or concerns that are associated with significant
distress and/or dysfunction. The fact that it is included
in a Not Elsewhere Classified section means that it is
in a category by itself, different from other Somatic
Symptom Disorders such as Functional Neurological
Disorder (previously, Conversion Disorder).
Pseudocyesis is defined by the DSM-5 as a false belief
of being pregnant that is associated with objective signs
and reported symptoms of pregnancy, which may include* Correspondence: tarinjj@uv.es
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reproduction in any medium, provided the orabdominal enlargement, reduced menstrual flow, amenor-
rhea, subjective sensation of fetal movement, nausea, breast
engorgement and secretions, and labor pains at the expected
date of delivery.
Cases of pseudocyesis nowadays are found more
frequently in rural undeveloped countries where women
usually are not examined by a physician or a midwife
until they are in labor or seek medical aid [2,3]. In
developed countries, women visit obstetricians in the
first trimester of pregnancy who have more accurate
means of diagnosis including pregnancy tests and
ultrasonographic examinations. These diagnostic pro-
cedures may help pseudocyetic women to be convinced
of their non-pregnant condition, that usually leads to
resolution of pseudocyesis within minutes or even sec-
onds. Furthermore, women from developed countries
in general are more educated and sophisticated, and
their emotional conflicts result in a more profound,
refined mode of expression than that of pseudocyesis
(cited by Pawlowski and Pawlowski [2]).
Table 1 shows the incidence of pseudocyesis registered
in several USA and African hospitals. The relative high
incidence of pseudocyesis found in these studies, exceptd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Incidence of pseudocyesis
Frequency Location Race/Ethnicity Reference
1/22000 births Boston Hospitals, USA ? [4]
1/344 of newly booked expectant mothers St. Vincent’s Hospital Ndubia,
Ebonyi State, Nigeria
African black [3]
1/250 maternity clinic admissions (24 out of 27 patients
had tried to conceive without success for 2 to 17 years)
Jefferson Hospital, Philadelphia, USA 85% (23/27) African-American
black; 15% (4/27) white
[5]
1/200 births Baragwanath Hospital, South Africa African black [6]
1/160 women who had previously being investigated
and managed for reproductive failure
Wad Medani Teaching Hospital, Sudan African black [7]
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that most African black cultures give to fertility together
with low educational background [3,6] and sterility prob-
lems [5,7]. For instance, in the Igbo culture of southeast
Nigeria, married women wish to become pregnant because
pregnancy and childbirth confirm womanhood and secure
the woman’s place in her husband family. This societal
pressure may precipitate pseudocyesis as a psychological
defense to intense stress if the woman proves to be infertile
[3]. Recently, it has been reported that African-American
women perceive higher average social messages to have
children than White women (social messages were assessed
in a national random-digit dial telephone survey via two
items: it is important to my partner that we have children;
and it is important to my parents that I have children) [8].
We should emphasize that the definition of pseudo-
cyesis contrasts with delusion of pregnancy, deceptive
or simulated pregnancy and erroneous pseudocyesis
(for review, see O’Grady and Rosenthal [9]). Delusion
of pregnancy is a Somatic Type (i.e., delusion that the
individual has some general medical condition) Delusional
Disorder classified by the DSM-5 within Schizophrenia
Spectrum and Other Psychotic Disorders. It refers to the
false belief of being pregnant in the absence of physical
sings suggestive of pregnancy that may be experienced by
psychotic women [10-12] and men [13,14]. According to
the DSM-5, the disorder is not a consequence of the direct
physiological effects of a substance (e.g., a drug of abuse, a
medication) or a general medical condition. Although at
first glance it appears that it is easy to distinguish between
true pseudocyesis (pseudocyesis vera) and delusion of
pregnancy, sometimes delusions of pregnancy present
along with physical traits of pseudocyesis [15-18] making
difficult to perform a differential diagnosis.
A deceptive or simulated pregnancy is a Factitious
Disorder Imposed on Self classified by the DSM-5 within the
category of Somatic Symptom Disorders. In this case, the
woman acknowledges being pregnant knowing that it is not
true ([19,20]; for review, see O’Grady and Rosenthal [9]).
Finally, erroneous pseudocyesis refers to cases when the
woman erroneously misinterprets symptoms suggestive of
pregnancy, including amenorrhea, galactorrhea and/orabdominal enlargement, resulting from either organic
diseases (e.g., hormone-secreting tumor [21-23], alcoholic
liver disease [24], cholecystitis [25], urinary tract infection
complicated by urine retention [26]) or exposure to a
substance (e.g., a medication [27-30]).
Whereas most studies have presented pseudocyesis
cases as medical curiosities, a few studies have focused
their attention on ascertaining the neuroendocrine/
endocrine mechanism underlying this condition. These
studies, however, have not reported consistent changes
in plasma levels of prolactin (PRL), follicle stimulating
hormone (FSH), luteinizing hormone (LH), growth hor-
mone (GH), estradiol (E2), progesterone (P) and testos-
terone (T) (for reviews, see Small [31] and O’Grady and
Rosenthal [9]). The lack of consistency among studies is
not at all surprising if we take into account the small
sample sizes and the different endocrine methodologies
(e.g., different blood sampling frequency or type of assay
for measuring hormones) used in these studies, as well
as the ambiguous or null psychiatric/psychologic and/or
diagnostic criteria applied to define and discriminate
between cases of pseudocyesis vera versus delusional,
simulated or erroneous pseudocyesis.
In this review, we aim to find epidemiological, psy-
chiatric/psychologic, gynecological and endocrine traits
associated with pseudocyesis vera in order to propose
neuroendocrine/endocrine mechanisms leading to the
development of pseudocyetic traits.
Methods
A review of the current and older literature on studies
on human pseudocyesis was performed. The review was
based on publications up to January 2013 identified by
PubMed database searches using the following key words:
pseudocyesis and women. In addition, a hand search was
done to explore the references cited in the primary
articles. Only studies in which women met the DSM-5
definition of pseudocyesis (see above) and provided clear
evidence that women did not suffer from simulated or
erroneous pseudocyesis were selected for entering into the
study. Furthermore, in order to exclude cases of delusion of
pregnancy and focus exclusively on pseudocyesis vera, only
Tarín et al. Reproductive Biology and Endocrinology 2013, 11:39 Page 3 of 12
http://www.rbej.com/content/11/1/39studies in which a psychiatric/psychologic evaluation
provided proof that women were non-psychotic were
included in the study (Table 2). Two exceptions, however,
were allowed: (1) a woman that refused psychiatric evalu-
ation but her hormonal responses to thyroid-stimulating
hormone (TRH) stimulation and dexamethasone suppres-
sion tests were similar to those seen in major depressive
disorders [32]. This woman was entered into the study
because most (8 out of 10 women) of the pseudocyetic
women included in Table 2 suffered from mild to major
depression; and (2) an unidentified member of a cohort of
5 women that was not psychologically evaluated for unre-
ported reasons [33]. This woman was included in Table 2
because the potential bias that her inclusion may intro-
duce in the analysis, if the woman suffered from delusion
of pregnancy, is relatively small. In Table 3 we provide
data from the studies excluded from the study that did
not meet the inclusion criteria.
The chronological age of pseudocyetic women included
in Table 2 ranged from 16 to 39 years. Eight women
suffered from mild to major depression, one woman was
not psychologically evaluated for unreported reasons [33]
and another did not meet the criteria for depression
disorder but exhibited a histrionic and hypochondriac per-
sonality [16]. As the majority of the pseudocyetic women
suffered from mild to major depression and 3 [32-35] out
of the 5 studies suggested that the endocrinological traits of
pseudocyetic women resemble those of polycystic ovarian
syndrome (PCOS), data from pseudocyetic women were
qualitatively compared with those reported for PCOS and
major depressive disorder.
PCOS is a heterogeneous disease characterized by
hyperandrogenemia (predominantly of ovarian origin:
the ovaries produce up to 60% of androgens, while the
remaining 40% is of adrenal origin), hirsutism, oligo- or
amenorrhea and anovulation, and is frequently associated
with hyperinsulinemia, insulin resistance syndrome,
increased cardiovascular risk and diabetes mellitus
(for reviews, see McCartney et al. [36], Rotterdam ESHRE/
ASRM-Sponsored PCOS Consensus Workshop Group [58]
and Burt Solorzano et al. [59]). Note as well that there are
many subgroups of depression differing from each other in
their neuroendocrine/endocrine traits. Thus, for the sake of
homogeneity, we chose the well-characterized major
depressive disorder group as a reference group.
It is important to mention that the studies included in
Table 2 used different endocrine methodologies (e.g.,
different blood sampling frequency or type of assay for
measuring hormones). For this reason, the absolute hor-
monal concentrations reported in these studies cannot be
compared among studies. Instead, Table 2 and Table 3
provide the authors’ original terminology that was used
to describe whether hormonal levels were “elevated”, “low”
or “within normal range” when compared to control datafrom either the own authors’ laboratory [33,34] or from
other contemporary sources [16,32,35].
Similarities and differences among pseudocyesis, PCOS
and major depressive disorder
Table 4 shows a summary of the traits that characterize
pseudocyesis, PCOS and major depressive disorder
according to the variables included in Table 2. The
comparative analysis shows that pseudocyetic women
share many endocrine traits with PCOS and major
depressive disorder, although these traits are more akin
to PCOS than to major depressive disorder. Note that the
fact that pseudocyetic women share many endocrine traits
with PCOS does not necessarily mean that pseudocyetic
women suffer from PCOS (we are not aware of any study
reporting the presence of polycystic ovaries in pseudocyetic
women). As mentioned above, pseudocyesis is a psychiatric
condition. It is not a consequence of either organic diseases
(including PCOS) or exposure to a substance.
Neuroendocrine/endocrine pathways of pseudocyesis
Most pseudocyetic women suffer from mild to major
depression, anxiety and/or emotional stress due to
psychologic conflicts or needs, such as women who
simultaneously wish for children and fear becoming
pregnant (for reviews, see Small [31], O’Grady and
Rosenthal [9] and Whelan and Stewart [88]) or women
who have an overwhelming desire to become pregnant
because of societal pressures [3,7]. In this context, we
should mention that patients with major depression
have a deficit in brain dopamine and norepinephrine
activity [89], and increased sympathetic nervous system
activity associated with a higher rate of entry to plasma
of norepinephrine released from sympathetic nerves
(norepinephrine spillover rate) [90,91] and elevated plasma
levels of norepinephrine [92]. In rodents, chronic psycho-
social stress is also associated with reduced brain dopamine
and norepinephrine activity and elevated plasma levels
of norepinephrine (for reviews, see Goddard et al. [93]
and Rasheed and Alghasham [94]). PCOS women also
show low dopamine hypothalamic tone (for review, see
Hernández et al. [95]).
Data from the present review indicate that pseudocyetic
women may have a deficit in brain dopamine activity.
This fact supports the notion that pseudocyetic women
may have a dysfunction of central nervous system catechol-
aminergic pathways involved in the regulation of anterior
pituitary hormone secretion. Dopamine [96] and norepin-
ephrine [97] have been recently identified in mice as potent
steroid-independent inhibitors of gonadotropin-releasing
hormone (GnRH) neuron excitability and firing. Moreover,
dopamine in women inhibits pulsatile LH (for review, see
Jaffe et al. [98]) and PRL (for review, see Ben-Jonathan and
Hnasko [48]) secretion. Thus, a deficit/dysfunction in brain
Table 2 Epidemiological, psychiatric/psychologic, gynecological and endocrinological traits of 10 pseudocyetic women analyzed in 5 studies that fulfilled the
inclusion criteria laid down in the Methods section
N° of
women
Women’s
age (y)
Psychiatric/
psychologic
traits
Gynecological
traits
LHa FSH LH/
FSHa
ratio
Tb E2 P GH PRL
c Cortisol
or DHEAS
Response to
inhibitors of
the pituitary-
adrenal axis
Response
to GnRH
TSH and/
or
response
to TRHe
Response to
dopamine
agonists
(bromocriptine,
apomorphine
and L-DOPA)f
or opiate
antagonists
(naloxone)g
Reference
1 16 Mild
depression
Amenorrhea (9
months) and
galactorrhea
Elevated
with
increased
frequency
of pulses
(mid-cycle
surge
levels)
Within
normal
range
≈ 5.7 – Within
the mid-
follicular
phase
range
slightly
higher
than the
follicular
phase
range
Normal
diurnal
episodic
secretion
Distinctly
elevated
(similar to
the mid-
cycle
surge)
– – – Basal TSH
within
normal
range
– [34]
1 39 Depression Amenorrhea (5
months) and
galactorrhea
≈ 0.2 IU/L ≈ 14 IU/
L
≈ 0.1 – Within
the
follicular
phase
range
Within
the
follicular
phase
range
– Within
the
normal
range
– – Normal
increase in
LH and
FSH after
GnRH
Normal
increase in
TSH and
PRL, and
paradoxical
increase in
GH (normal
basal levels
of TSH)
Normal decrease
in PRL after
bromocriptine
and normal
decrease in PRL
and blunted
increase in GH
after
apomorphine
[35]
1 27 Likely unipolar
depressive
disorder
Amenorrhea (9
months) and
galactorrhea
Within
follicular
phase
range
Within
follicular
phase
range
2.0 Within mid-
follicular
phase range
Within
the mid-
follicular
phase
range
Within
mid-
follicular
phase
range
– Within
the
normal
range
Minimally
elevated
DHEAS
levels
Normal
suppression of
A.M. cortisol but
ACTH remained
elevated after
overnight low-
dose (1 mg)
dexamethasoned
– Small
increase in
TSH, normal
increase in
PRL and
paradoxical
increase in
GH (normal
basal levels
of TSH and
T4)
– [32]
5 19, 29, 33,
34, 35
4 women with
depression and
hysteria
Amenorrhea
(4–15 months)
and
galactorrhea
Within
normal
range
Within
normal
range
8.0,
6.6,
2.7,
2.9,
4.4
– Within
normal
range (4
women)
1 woman
within the
follicular
phase
range,
and 4
women
slightly
higher
than the
follicular
phase
range
– Slightly
elevated
(4
women)
and
within
the
normal
range (1
woman)
– – – – No increase in
LH or PRL after
naloxone
[33]
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Table 2 Epidemiological, psychiatric/psychologic, gynecological and endocrinological traits of 10 pseudocyetic women analyzed in 5 studies that fulfilled the
inclusion criteria laid down in the Methods section (Continued)
1 30 Histrionic
personality
suffering from
major
depressive
disorder and
borderline
personality
disorder
Amenorrhea (7
months) and
galactorrhea
Elevated
with
frequency
of pulses
higher
than late-
follicular
phase
Within
normal
range
≈
11.3
Consistently
elevated
Elevated
(late-
follicular
phase
levels)
Not
elevated
(late-
follicular
phase
levels)
Decreased
nocturnal
peaks of
GH
Normal
levels
with
greater
release
during
sleep
than
during
daytime
Normal
cortisol
levels
rising
during
sleep and
reaching a
maximum
at 08.00-
09.00 h
– – – Decrease in PRL
levels and no
increase in GH
after L-DOPA
[16]
1 38 Histrionic and
hypochondriac
personality
Amenorrhea (>
5 months) and
galactorrhea
Normal
with
frequency
of pulses
similar to
late-
follicular
phase
Within
normal
range
≈ 2.9 Consistently
elevated
Elevated
(late-
follicular
phase
levels)
Not
elevated
(late-
follicular
phase
levels)
Decreased
nocturnal
peaks of
GH
Normal
levels
with
greater
release
during
sleep
than
during
daytime
Normal
cortisol
levels
rising
during
sleep and
reaching a
maximum
at 08.00-
09.00 h
– – – Decrease in PRL
and no increase
in GH after L-
DOPA
[16]
aDespite discrepancies among studies in levels of LH, all the studies included in Table 2 excluding one [35] evidenced LH/FSH ratios higher than 2.0. Moreover, the two studies [16,34] that measured and analyzed pulsatile patterns of LH in 3 women
reported increased (“higher than or similar to the late follicular phase” [16] or “similar to the mid-cycle surge” [34]) frequency of pulses. It is important to stress that these women exhibited high levels of E2 similar to those found at the late-follicular
phase [16], and high levels of PRL similar to those observed mid-cycle just before ovulation [34]. As the frequency of LH pulses increases during the pre-ovulatory period in women with normal menstrual cycles (for review, see McCartney et al. [36]),
these data suggest that the 3 pseudocyetic women with high frequency of pulses were in the pre-ovulatory phase of the menstrual cycle at the time blood samples were collected. However, it is very unlikely that the 3 pseudocyetic women restarted
ovarian cyclicity just before going to the doctor after being amenorrheic for a long (5 to 7 months). On the contrary, women may have restarted ovarian cyclicity after being informed of her non-pregnant state. In fact, 2 women menstruated 3 [16] and 2
[34] weeks, respectively, after being told that they were not really pregnant (basal hormone determinations were performed before women were informed of their non-pregnant state). Of note, in the woman that menstruated 2 weeks after disclosure of
diagnosis, the distended abdomen disappeared within 30 min and the basal levels of LH, PRL and E2 decreased shortly after being informed of her false pregnancy. All these circumstances support the notion that the higher frequency of LH pulses
evidenced in these women was indeed due to their pseudocyetic condition rather than to spontaneous resumption of ovarian cyclicity before going to the doctor.
bIn these studies, total serum T concentrations were measured by direct radioimmunoassay, a method that suffers from a number of serious problems. This assay often overestimates T concentrations and has limited accuracy at T < 10.4 nmol/L at
concentrations typically found in women [37]. Moreover, total serum T levels vary across the menstrual cycle. In normal cycling women, T levels are relatively high at the mid-follicular phase, peaking on the day of LH peak [38,39]. As mentioned above,
despite the 2 women analyzed by Starkman et al. [16] displayed LH pulse characteristics and E2 and P levels similar to those found at the late-follicular phase, these traits were likely associated to their pseudocyetic condition. Therefore, the “consistently
elevated” T levels reported by Starkman et al. [16] cannot be ascribed to women being at the late-follicular phase (when serum T levels are highest). In fact, the 2 women exhibited T concentrations (5.2 and 4.2 nmol/L, respectively) much higher than
those observed in normal cycling women at mid-cycle using direct radioimmunoassay (≈3.3 nmol/L [38]), isotope dilution-liquid chromatography-tandem mass spectrometry (1.7 nmol/L [39]) or automated delayed one step chemiluminescent
microparticle immunoassay (2.0 nmol/L [39]).
cAll the women included in Table 2 had galactorrhea despite 50% of them being normoprolactinemic. The absence of correlation between the presence of galactorrhea and levels of PRL may be explained by the fact that blood sample collections were
performed in the morning in the majority of the studies. Such a sampling schedule may have concealed the possible occurrence of transient nocturnal hyperprolactinemia associated with galactorrhea and diurnal normoprolactinemia as reported in
infertile normoprolactinemic women [40]. In fact, the only study in Table 2 that determined PRL levels in 2 pseudocyetic women during the night [16] reported rising levels during sleep but normal levels during the day. Although the pattern of pituitary
PRL release in women with normal cycles follows this circadian rhythm (for review, see Bouilly et al. [41]), the nocturnal PRL concentrations (≈869.6 to ≈ 2174.0 pmol) reported by Starkman et al. [16] are more consistent with those found at night in
women with nocturnal hyperprolactinemia, galactorrhea and diurnal normoprolactinemia (608.7 to 1130.4 pmol) than with those displayed by women with normal cycles (347.8 to 608.7 pmol) [40]. Interestingly, the galactorrhea exhibited by women with
nocturnal hyperprolactinemia and diurnal normoprolactinemia improved in ≈ 90% (8/9) of cases after treatment with the dopamine agonist bromocriptine [40]. These facts suggest that normoprolactinemic pseudocyetic women (50% in the present
review) may have occult hyperprolactinemia due to a deficit in brain dopamine activity.
dThe discrepancy between the cortisol and adrenocorticotropin hormone (ACTH) response to dexamethasone may be due to the low sensitivity and specificity of the ACTH assay used in this study [42]. However, the fact that after resolution of
pseudocyesis both ACTH and cortisol levels decreased after dexamethasone administration suggests that the discordant response observed by Ayers and Seiler [32] was associated with pseudocyesis.
eAfter resolution of pseudocyesis, women had no GH response to TRH [32,35] and the blunted or reduced thyroid-stimulating hormone (TSH) response reverted to normal [32] which occurs in patients with major depression after clinical recovery [43,44].
The mechanism of the paradoxical response of GH to TRH has not been yet elucidated (cited by Arita et al. [45]). However, some authors have speculated about the occurrence of a disruption of the normal neuroendocrine regulatory mechanisms and/or
alteration of the cellular receptors of the somatotroph cells in adenomatous tissue [46].
fDopamine stimulates hypothalamic GH-releasing hormone (GHRH) release [47] but inhibits the high intrinsic PRL secretory activity of the pituitary lactotrophs as well as PRL gene expression and lactotroph proliferation [48]. However, the elevated levels
of T displayed by pseudocyetic women may decrease the response of GH to apomorphine and L-3,4-dihydroxyphenylalanine (L-DOPA) since T directly stimulates somatostatin [a.k.a. GH-inhibiting hormone (GHIH) or somatotropin release-inhibiting factor
(SRIF)] release from the periventricular nucleus of the hypothalamus (for review, see Spiliotis [49]). It should be emphasized that the decreased GH secretion after apomorphine evidenced by Tulandi et al. [35] reverted to normal after resolution
of pseudocyesis.
gIt is known that endogenous opioid peptides inhibit simultaneously LH and PRL secretion mediated by steroid-dependent suppression of hypothalamic release of GnRH (for review, see Yen et al. [50]). In fact, women with normal cycles exhibit a positive
LH and PRL response to naloxone during the late-follicular and mid-luteal phases (when E2 and P levels are relatively high) but not in the early-follicular phase of the menstrual (for review, see Yen et al. [50]). Note that although the pseudocyetic women
analyzed by Devane et al. [33] had P levels “slightly higher” [mean ± standard error of the mean (SEM): 8.9 ± 2.5 nmol/L] than the normal follicular phase range (<3.2 nmol/L [33]), levels of E2 (200.8 ± 47.7 pmol/L) were within the early follicular range (73.4
to 212.2 pmol/L [51]). Thus, the presence of relatively low levels of E2 may explain the absence of response of LH and PRL to naloxone evidenced by Devane et al. [33] such as occurs in women with normal cycles in the early-follicular phase cycle or in
hypogonadal women (for review, see Yen et al. [50]) and, therefore, it does not support a role for brain opioid peptides in pseudocyesis.
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Table 3 Epidemiological, psychyatric/psychologic, gynecological and endocrinological traits of pseudocyetic women from studies discarded because they did
not meet the inclusion criteria laid down in the Methods section
N° of
women
Women’s
age (y)
Psychiatric/
psychologic
traits
Gynecological
traits
LH FSH LH/
FSH
ratio
T E2 P GH PRL Cortisol or
DHEAS
Response
to GnRH or
EBa
TSH and/or
response to
TRH
Response to
dopamine
agonistsb or
antagonistsc
Reference
2 19, and 33 – Amenorrhea (6
and 8 months,
respectively),
galactorrhea,
and presence
of a
proliferative
endometrium
Total
gonadotropin
activity below
the normal
limits found in
normal
cycling
women
Total
gonadotropin
activity below
normal limits
found in
normal
cycling
women
– – Total
estrogen
activity
below
normal
range
found in
normal
cycling
women
– – Distinctly
elevated
– Marked
increase in
LH and, to a
lesser extent,
FSH after
GnRH
Marked increase
in PRL and
normal increase
in TSH (basal
levels of total T4,
free T4 and
thyroid binding
globulins within
normal range)
– [52]
6 38.0 ± 2.5c – Amenorrhea
and
galactorrhea
Slightly
elevated but
within normal
range
Within normal
range
11.5 – – – – Markedly
elevated
– – – – [53]
6 42.8 ± 6.3c – Amenorrhea
without
galactorrhea
Markedly
elevated
Elevated 21.3 – – – – Within
normal
range
– – – – [53]
2 40 and 26 No treatment
with
tranquilizers
in the past
Amenorrhea (3
and 7 months,
respectively),
galactorrhea,
and recurrence
of
pseudocyesise
Normal Normal 0.6
and
2.1
– Within
the
follicular
phase
range
Within
the
follicular
phase
range
– Within the
normal
range
– Marked or
normal
increase in
LH and
normal
increase in
FSH after
GnRH
Marked increase
in PRL, normal
increase in TSH
and paradoxical
increase in GH
after TRH
(normal basal
levels of TSH
and T4, and
normal fasting
blood glucose
levels)
Blunted increase
of GH (PRL was
not measured)
after
apomorphinea in
one woman and
no response of
GH and normal
decrease in PRL
after
bromocriptinea in
the other woman
[54]
1 16 – Amenorrhea (5
months)
without
galactorrhea,
and presence
of a
proliferative
endometrium
Elevated
(within the
climacteric
range)
Within the
follicular
phase range
2.9 – Within
the
follicular
phase
range
Within
the
follicular
phase
range
– Within the
normal
range
– Normal
increase in
LH and FSH
after GnRH;
and normal
positive
feedback of
LH after EB
Normal PRL and
TSH increase
after TRH
(normal basal
levels of TSH)
Normal increase
in PRL after
metoclopramideb
[55]
1 17 – Amenorrhea (8
months)
without
galactorrhea,
and the
presence of a
proliferative
endometrium
Within the
follicular
phase range
Within the
follicular
phase range
0.9 – Within
the
follicular
phase
range
Within
the
follicular
phase
range
– Within the
normal
range
– Normal
increment in
LH and FSH
after GnRH,
and normal
positive
feedback of
LH after EB
Normal PRL and
TSH increase
after TRH
(normal basal
levels of TSH)
Normal increase
of PRL after
metoclopramideb
[55]
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Table 3 Epidemiological, psychyatric/psychologic, gynecological and endocrinological traits of pseudocyetic women from studies discarded because they did
not meet the inclusion criteria laid down in the Methods section (Continued)
5 19-35
(median
22)
Women with
a psychiatric
condition
that
precluded
informed
consent were
excluded
Amenorrhea
(5.5-12.5
months),
galactorrhea (3
women), and
hirsutism (3
women, one of
them with
clitoromegaly)
Below the
upper normal
limit (<20 IU/
L) with either
low-normal or
definitely low
pulse
amplitudes
(early-follicular
phase)
Within the
follicular
phase range
1.2 Elevated
in 3
women.
Another
women
with
mildly
elevated
FAIf
Within
the early-
follicular
range
Within
the
early-
follicular
range.
– Normal
levels with
greater
release
during
sleep than
during
daytime (1
women
displayed
high PRL
levels)
– – – – [56]
9 24.9 ± 2.2d – Amenorrhea
(3–12 months)
and
galactorrhea (8
women)
Within the
follicular
phase range
Within the
follicular
phase range
1.1 – 6
women
with
lower
levels
than the
follicular
phase
range
2
women
with
luteal
phase
levels
5 women
exhibited
impaired GH
responses to
hypoglycemia
(4 of them
also displayed
E2 deficiency)
Within
follicular
phase
range
Normal
responses of
cortisol to
hypoglycemia
(peak
responses
exceeded 600
nmol/L)
4 women
with
exaggerated
LH response
(2 of them
also with
exaggerated
FSH
response)
after GnRH
Normal PRL and
TSH increase
after TRH (1, 1
and 2 women
had exaggerated
PRL, GH and TSH
responses,
respectively)
Decrease in PRL.
In 4 women, no
increase in GH
after L-DOPAa (3
of these women
displayed also
impaired GH
response to
hypoglycemia)
[57]
aEstradiol benzoate.
bDopamine agonist.
cDopamine antagonist.
dMean ± SEM.
eThis was the 40-year-old woman with 3 months of amenorrhea and a LH: FSH ratio of 0.6 [the same woman analyzed by Tulandi et al. [35] (see Table 2)].
fFree androgen index.
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Table 4 Comparative analysis of pseudocyesis, PCOS and major depressive disorder traits according to the variables
included in Table 2a
Variables included in Table 2 Pseudocyesis PCOS Major depressive disorder
Amenorrhea Yes Yes [36,59] No [60]
Galactorrhea Yes Yesb No [60]
LH/FSH ratio Increased Increasedc ?
Frequency of LH pulses Increased Increasedc Decreased frequency and
dysrhythmic pulses [60]
T levels Elevated Elevated [61] Elevated [62]
E2 levels Within the (broad) normal ranges Within the (broad) normal
ranges [63]
Decreased levels in the follicular phased
P levels Within or slightly higher than
the follicular phase range
Within either the follicular
phase range or the lutheal
phase rangee
Normal P levels on the first day after
menstruation [62] and higher P levels
in the luteal phase [64]
GH levels Decreased nocturnal peaks
and normal diurnal episodic
secretion
Low, normal or elevated
levels with impaired
diurnal secretion [65]
Decreased nocturnal secretion [66]
PRL levels Normal (putative occult
hyperprolactinemia), slightly
elevated or distinctly elevated
Hyperprolactilemia
(10-15% of PCOS women) [36]
Normal [62]
DHEAS levels Minimally elevated Elevated (20-33% of
PCOS women [67])
Normal [68]
Cortisol levels Normal Normal [67] Disturbed diurnal rhythms, higher
evening levels and accentuated
post-awakening surge [69]
Response of ACTH to dexamethasone Escape from suppression ? Some individuals escape from
suppression [42]
Response of cortisol to dexamethasone Suppression Suppression [70] Some individuals escape from
suppression [42]f
Response of LH and FSH to GnRH Normal increase Higher increase in LH and
normal increase in FSH [71]
Normal increase [62]
Response of GH to TRH Paradoxical increase Paradoxical increase
(≈42% of PCOS women [46])
Paradoxical increase [43]
Response of TSH to TRH Normal or small increase ? Small increase [43,44]
Response of GH to dopamine agonists Deficient or reduced increase Deficient or reduced
increase [72,73]g
Normal [74]or reduced
increase [75-77]
Response of LH and/or PRL to
opioid receptor antagonists
No increase in LH and PRL Small increase in LH and
no increase in PRL [78,79]
Increase in LH [80]h
aCommon traits of pseudocyesis, PCOS and/or major depressive disorder are highlighted using bold text.
bAlthough the true incidence of galactorrhea in PCOS remains unclear and is probably only 1 or 2%, a study published in 1980 [81] reported that ≈ 24% of PCOS
women show galactorrhea irrespectively of the concomitant presence of either hyperprolactinemia (≈14%) or normoprolactinemia (≈10%).
cPCOS women have increased GnRH pulse frequency because of androgen-mediated decreased GnRH sensitivity to P feedback inhibition. The higher GnRH pulse
frequency increases LH pulsatility and favors LH production over FSH (for reviews, see McCartney et al. [36] and Burt-Solorzano et al. [59]).
dWhereas untreated premenopausal women suffering from major depression display E2 levels on the first day after menstruation similar to those found in healthy
age-matched control women [62], they often have plasma levels of E2 in the follicular phase significantly lower than control healthy women
(for reviews, see Swaab et al. [82] and Williams et al. [60]), although they exhibit higher amplitudes of diurnal E2 rhythms [83].
eLevels in PCOS women show the typical changes associated with either anovulation (P deficiency, i.e., within the follicular phase range) or ovulation (within the luteal phase
range) [84,85]. Note that nearly 12% of oligo- or amenorrheic PCOS women show signs of spontaneous ovulation based on random P assessment [86].
fSome of the discrepancies between cortisol and ACTH responses to dexamethasone in major depressed individuals may be due to the low sensitivity and
specificity of the ACTH assays used in some studies [42].
gThe hyperandrogenemia in PCOS may contribute to the relatively reduced response of GH to dopamine agonists (for review, see Spiliotis [49]).
hThe study by Martín del Campo et al. [80] is methodologically flawed. In particular, they analyzed a heterogeneous group of women with major depression
(4 post-menopausic, 2 eumenorrheic and one with irregular cycles) and did not control for the phase of the menstrual cycle. In addition, they used both
women and men as control subjects. Despite these methodological deficiencies, there is evidence of dysregulated endogenous opioid emotion regulation
circuitry in women with major depressive disorder [87].
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GnRH, LH and PRL and an elevated LH/FSH ratio.
These endocrine changes may induce hypomenorrhea
or amenorrhea, galactorrhea and diurnal and/or nocturnalhyperprolactinemia - traits found in most pseudocyetic
women. Also, the reduced brain catecholaminergic activity
displayed by pseudocyetic women may combine/interact
with a drop in steroid feedback inhibition of GnRH. In
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pseudocyetic women may decrease GnRH sensitivity to
P feedback inhibition resulting in increased GnRH
pulse frequency, elevated LH pulsatility and higher LH
production over FSH such as occurs in PCOS women
(for reviews, see McCartney et al. [36] and Burt-Solorzano
et al. [59]). Finally, the increased sympathetic nervous
system activity likely shown by pseudocyetic women may
be implicated, not only in the apparent fetal movements
and labor pains at the expected date of delivery felt by some
pseudocyetic women, but also in the typical abdominal
enlargement displayed by most pseudocyetic women.
Several authors have proposed a mixture of causes to
explain the physiological mechanism by which abdominal
swelling takes place in pseudocyetic women. This mixture
of causes includes chronic contraction of the diaphragmatic
muscle (this contraction pushes the bowel downward in
the abdominal cavity), assumption of a lordotic posture,
increased omental and abdominal wall fat, and mild to
marked constipation and/or bowel distention (for reviews,
see Small [31], O’Grady and Rosenthal [9] and Whelan
and Stewart [88]). However, the distended abdomen,
that may remain bloated for months immediately
(within minutes or even seconds) disappears, with or
without release of flatus, after pseudocyetic women are
convinced of their non-pregnant state or under anesthesia.
This observation indicates that although increased omental
and abdominal wall fat, and mild to marked constipation
and/or bowel distention may contribute to abdominal
enlargement, they are not primary causes of abdominal
protrusion. Furthermore, unlike normal pregnancy, the
umbilicus does not become everted, the abdominal
distension is uniform and rounded, and the abdominal
wall presents a rubbery, tense muscular tone being
tympanic on percussion. All these facts point to the
diaphragm and/or certain groups of muscles of the abdom-
inal wall as the primary cause of abdominal enlargement. In
particular, pseudocyetic women may experience chronic
contraction of the diaphragm accompanied by abnormal
patterns of contraction/relaxation of the anterior abdominal
and internal oblique muscles. This mechanism, called
abdomino-phrenic dyssynergia, has been observed in
patients with abdominal bloating and distension after
colonic-gas-load-induced abdominal distension [99].
Interestingly, literature shows cases of persistent [100]
or spasmodic (spasms resembling those of a woman
in labor [101]) hysterical abdominal proptosis likely
resulting from abdomino-phrenic dyssynergia.
It is worth mentioning that, in contrast to normal
individuals that can push out the abdominal wall only
for a relatively short period of time even in the presence
of the quietest respiration, persistent hysterical abdominal
proptosis is unaffected by a cough or by a sneeze, nor
by emptying the bladder or by straining at stool [100].However, it disappears after relaxing the patient’s dia-
phragm by having the patient take a deep inspiration
followed by a sudden expiration or by having the patient
hold her/his breath as long as possible such as occurs in
pseudocyesis (for reviews, see Alvarez [102] and O’Grady
and Rosenthal [9]).
Importantly, the 2 phrenic nerves that originate in the
neck (mainly from the 4th cervical nerve, but which also
receive contributions from the 5th and 3rd cervical nerves)
and pass down between the lung and heart to reach
the diaphragm, contain not only motor fibers but also
proprioceptive and sympathetic fibers to the diaphragm,
and sensory fibers to the pleura and pericardium.
Therefore, dysfunction of the sympathetic nervous system
in pseudocyetic women, mediated directly via impulses
transmitted through the sympathetic nervous system
and/or indirectly via plasma norepinephrine released from
sympathetic nerves or secreted from the adrenal medulla,
may induce abdomino-phrenic dyssynergia resulting in
abdominal protrusion.
Concluding remarks
In this literature review, we have analyzed epidemiological,
psychiatric/psychologic, gynecological and endocrine traits
of 10 pseudocyetic women reported in 5 selected studies
after applying stringent criteria to discriminate between
cases of pseudocyesis vera versus delusional, simulated or
erroneous pseudocyesis. The analysis performed shows
that pseudocyetic women share many endocrine traits with
PCOS and major depressive disorder, although these traits
are more akin to PCOS than to major depressive disorder.
The reviewed data support the notion that pseudocyetic
women may have: increased sympathetic nervous system
activity; dysfunction of central nervous system catechol-
aminergic pathways involved in the regulation of hormone
secretion from adenohypophysis; and decreased steroid
feedback inhibition of GnRH. These neuroendocrine/endo-
crine disorders may cause hypomenorrhea or amenorrhea,
galactorrhea, diurnal and/or nocturnal hyperprolactinemia,
abdominal distension and apparent fetal movements and
labor pains at the expected date of delivery - traits exhibited
by most pseudocyetic women. However, other neuroendo-
crine/endocrine pathways not yet analyzed in pseudocyetic
women may also be involved in the development of
pseudocyetic traits. These may include, the hypothalamic-
pituitary-adrenal axis; neurotransmitters controlling GnRH
neuron excitability [96]; and dopamine stimulators and
inhibitors of PRL secretion (for review, see Ben-Jonathan
and Hnasko [48]).
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